AzTrials
AzTrials

SpondylolisthesisNCT01024699

XLIF® vs. MAS®TLIF for the Treatment of Symptomatic Lumbar Degenerative Spondylolisthesis With or Without Central Stenosis.

An observational study of Spondylolisthesis, run by NuVasive at 9 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine differences in the XLIF and TLIF procedures with respect to perioperative variables in adult patients with low-grade symptomatic spondylolisthesis. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Spondylolisthesis
How many people
55 participants
Where
9 sitesUnited States
Study dates
Nov 2009to Feb 2015
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Study population will consist of patients from participating site locations.

Who may be able to join

  • Male and female patients who are at least 18 years of age;
  • Patients who present with symptomatic Grade I or II degenerative spondylolisthesis at 1 or 2 contiguous lumbar levels between L1 and L5 and are surgical candidates for interbody lumbar fusion surgery; symptoms should include radiculopathy and/or neurogenic claudication with or without back pain;
  • Patients who have been unresponsive to at least 6 months of conservative treatments or exhibit progressive neurological symptoms in the face of conservative treatment;
  • Patients who understand the conditions of enrollment and are willing to sign an informed consent to participate in the study.

Who cannot join

  • Patients with lumbar pathologies requiring treatment at more than 2 levels;
  • Patients who have had previous lumbar fusion surgery;
  • Patients with lytic spondylolisthesis or a defect of the pars interarticularis;
  • Patients with radiographic confirmation of Grade IV facet joint disease or degeneration;
  • Patients with non-contained or extruded herniated nucleus pulposus

Trial locations and contacts

9 sites in 1 country.

9 sites in 1 country

United States9 sites
  • Duke University Medical Center

    Durham, North Carolina, 27710

  • The Methodist Hospital

    Houston, Texas, 77030

  • St. Vincent-Jacksonville

    Jacksonville, Florida, 32204

  • Celebration Florida Hospital

    Kissimmee, Florida, 34747

  • Orthopaedic Clinic-Riverside Campus, University of Minnesota

    Minneapolis, Minnesota, 55454

  • Northwest Orthopaedic Specialists, P.S.

    Paducah, Kentucky, 42003

  • Spine and Sports Institute

    Richland, Washington, 99352

  • St. Joseph's/Candler Health System

    Savannah, Georgia, 31405

  • Northwest Orthopaedic Specialists, P.S.

    Spokane, Washington, 99208

Other trials in United States

About this study

Official title: A Prospective Multi-Center Randomized Evaluation of the Clinical and Radiographic Outcomes of XLIF® Compared With MAS® TLIF for the Treatment of Symptomatic Lumbar Degenerative Spondylolisthesis With or Without Central Stenosis

The purpose of this study is to determine differences in the XLIF and TLIF procedures with respect to perioperative variables in adult patients with low-grade symptomatic spondylolisthesis.

Read the detailed description

The study is a prospective multi-center randomized evaluation of clinical and radiographic outcomes of two commonly used lumbar interbody fusion procedures (XLIF and TLIF) in adult patients with low-grade symptomatic spondylolisthesis. The study seeks to identify differences between the procedures with respect to perioperative variables.

Medical subject headings
Spondylolisthesis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01024699
Study groupRoleWhat they receive
XLIFThis group will have the XLIF procedure done.
MAS TLIFThis group will have the MAS TLIF procedure done.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The average improvement in clinical function (ODI) at 24 months compared with baseline, for each procedure.

    Measured: 24 months

Secondary outcomes (1)
  1. The average improvement in pain (VAS) at 24 months compared with baseline, for each procedure.

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Dec 2009 (estimated)
  2. Study startNov 2009
  3. Primary completionFeb 2015
  4. Study completionFeb 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
55 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01024699
Sponsor's protocol ID
NUVA.X0901
Status last verified
Dec 2025
First submitted
1 Dec 2009
Last updated
24 Dec 2025
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Spondylolisthesis, run by NuVasive at 9 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 9 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The average improvement in clinical function (ODI) at 24 months compared with baseline, for each procedure. (time frame: 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in